Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Stanford University
Eli Lilly and Company
University of California, San Francisco
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Centre, Singapore
TYK Medicines, Inc
H. Lee Moffitt Cancer Center and Research Institute
Icahn School of Medicine at Mount Sinai
Radboud University Medical Center
EMD Serono
University of Kansas Medical Center
NYU Langone Health
Case Comprehensive Cancer Center